JO3470B1 - مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv - Google Patents

مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv

Info

Publication number
JO3470B1
JO3470B1 JOP/2013/0284A JOP20130284A JO3470B1 JO 3470 B1 JO3470 B1 JO 3470B1 JO P20130284 A JOP20130284 A JO P20130284A JO 3470 B1 JO3470 B1 JO 3470B1
Authority
JO
Jordan
Prior art keywords
reverse transcriptase
hiv reverse
transcriptase inhibitors
pyrimidin
phenoxy
Prior art date
Application number
JOP/2013/0284A
Other languages
English (en)
Inventor
Burgey Christopher
Luo Yunfu
Lei Zhiyu
Han Yongxin
Patel Mehul
Li Yaozong
L Arrington Kenneth
Xu Jiayi
Gilfillan Robert
Sing Li Chun
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of JO3470B1 publication Critical patent/JO3470B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بمركبات لها الصيغة (1): </span> <img src="file:///C:/Users/Darwish.Q/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /> عبارة عم مثبطات إنزيم ترانسكريبتاز العكسي ل <span dir="LTR">HIV</span> حيث تكون <span dir="LTR">R1 </span> و <span dir="LTR">R2</span> و <span dir="LTR"> RE</span> و <span dir="LTR">L</span> و <span dir="LTR">M</span> و <span dir="LTR">Z</span> كما هي محددة في هذا الطلب. تتسم المركبات التي لها الصيغة 1 و الأملاح و العقاقير الأولية المقبولة صيدلانيا منها بفائدتها في تثبيط إنزيم ترانسكربيتاز العكسي ل <span dir="LTR">HIV </span> و الوقاية من و علاج العدوى ب <span dir="LTR">HIV</span>، و في الوقاية من- تأخير ظهور أو تطور- و علاج متلازمة نقص المناعة المكتسبة (<span dir="LTR">AIDS</span>). يمكن استخدام المركبات و أملاحها كمكونات في تركيبات صيدلانية، و بشكل خياري في توليفة مع فيروسات مضادة أو معدلات مناعية أو أجسام مضادة أو لقاحات أخرى.
JOP/2013/0284A 2012-10-08 2013-09-29 مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv JO3470B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012001358 2012-10-08

Publications (1)

Publication Number Publication Date
JO3470B1 true JO3470B1 (ar) 2020-07-05

Family

ID=49354986

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0284A JO3470B1 (ar) 2012-10-08 2013-09-29 مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv

Country Status (46)

Country Link
US (3) US9469634B2 (ar)
EP (3) EP2903977B1 (ar)
JP (2) JP5877281B2 (ar)
KR (1) KR101696128B1 (ar)
CN (1) CN104822670B (ar)
AP (1) AP2015008355A0 (ar)
AR (1) AR092876A1 (ar)
AU (1) AU2013329552B8 (ar)
BR (1) BR112015007742B8 (ar)
CA (1) CA2887312C (ar)
CL (1) CL2015000880A1 (ar)
CO (1) CO7350655A2 (ar)
CR (1) CR20150183A (ar)
CY (3) CY1119655T1 (ar)
DK (3) DK2903977T3 (ar)
DO (1) DOP2015000082A (ar)
EA (1) EA033436B1 (ar)
EC (1) ECSP15018618A (ar)
ES (3) ES2770774T3 (ar)
GE (1) GEP20186838B (ar)
GT (1) GT201500088A (ar)
HR (3) HRP20171819T1 (ar)
HU (3) HUE048670T2 (ar)
IL (1) IL238090B (ar)
JO (1) JO3470B1 (ar)
LT (3) LT3295942T (ar)
MA (1) MA37959A2 (ar)
MD (1) MD4625C1 (ar)
ME (1) ME02918B (ar)
MX (1) MX355040B (ar)
MY (1) MY192716A (ar)
NI (1) NI201500048A (ar)
NO (1) NO2903977T3 (ar)
NZ (1) NZ706729A (ar)
PE (1) PE20151787A1 (ar)
PH (1) PH12015500764B1 (ar)
PL (3) PL3656384T3 (ar)
PT (3) PT3295942T (ar)
RS (3) RS63112B1 (ar)
SG (1) SG11201502620UA (ar)
SI (3) SI2903977T1 (ar)
TN (1) TN2015000106A1 (ar)
TW (2) TWI538907B (ar)
UA (1) UA114006C2 (ar)
WO (1) WO2014058747A1 (ar)
ZA (1) ZA201503143B (ar)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
EP3046912A1 (de) 2013-09-16 2016-07-27 Bayer Pharma Aktiengesellschaft Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten
EP3785714A1 (en) * 2014-04-01 2021-03-03 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
US10350165B2 (en) * 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
AU2018334290A1 (en) 2017-09-18 2020-04-02 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US20210213041A1 (en) 2018-02-06 2021-07-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
SI3788040T1 (sl) 2018-04-30 2023-07-31 Ribon Therapeutics Inc. Piridazinoni kot zaviralci parp7
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
IL281438B2 (en) 2018-09-18 2023-12-01 Goldfinch Bio Inc Pyridazinones and methods of use thereof
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
EP3898595B1 (en) * 2018-12-18 2024-05-01 Merck Sharp & Dohme LLC Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3942043A2 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
MX2021012310A (es) 2019-04-11 2021-11-12 Goldfinch Bio Inc Formulación de secado por aspersión de un inhibidor de trpc5 de piridazinona.
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12371421B2 (en) 2019-04-29 2025-07-29 Ribon Therapeutics, Inc. Solid forms of a PARP7 inhibitor
CA3141143A1 (en) * 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Pyridinone derivatives as selective cytotoxic agents against hiv infected cells
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
MX2022004049A (es) * 2019-10-04 2022-07-11 Goldfinch Bio Inc Tratamiento basado en biomarcadores de la glomeruloesclerosis focal y segmentaria y de la enfermedad renal diabetica.
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
MX2022005216A (es) 2019-10-30 2022-06-02 Ribon Therapeutics Inc Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
EP4066839A4 (en) 2019-11-28 2023-12-27 Shionogi & Co., Ltd PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
CN116670154A (zh) 2020-07-24 2023-08-29 总医院公司 增强的病毒样颗粒及使用其递送至细胞的方法
JP2023543803A (ja) 2020-09-24 2023-10-18 ザ ブロード インスティテュート，インコーポレーテッド プライム編集ガイドｒｎａ、その組成物、及びその使用方法
EP4274894A2 (en) 2021-01-11 2023-11-15 The Broad Institute, Inc. Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision
WO2023275230A1 (en) * 2021-07-01 2023-01-05 Janssen Pharmaceutica Nv 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
JP2024530487A (ja) 2021-08-06 2024-08-21 ザ ブロード インスティテュート，インコーポレーテッド 改善されたプライムエディターおよび使用方法
WO2023076898A1 (en) 2021-10-25 2023-05-04 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
US20250064979A1 (en) 2021-12-03 2025-02-27 The Broad Institute, Inc. Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
WO2023205687A1 (en) 2022-04-20 2023-10-26 The Broad Institute, Inc. Improved prime editing methods and compositions
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
WO2024077267A1 (en) 2022-10-07 2024-04-11 The Broad Institute, Inc. Prime editing methods and compositions for treating triplet repeat disorders
EP4619515A1 (en) 2022-11-17 2025-09-24 The Broad Institute, Inc. Prime editor delivery by aav
WO2024168147A2 (en) 2023-02-09 2024-08-15 The Broad Institute, Inc. Evolved recombinases for editing a genome in combination with prime editing
WO2024206125A1 (en) 2023-03-24 2024-10-03 The Broad Institute, Inc. Use of prime editing for treating sickle cell disease
US20250026759A1 (en) 2023-07-07 2025-01-23 Merck Sharp & Dohme Llc Tetrahydroquinazoline derivatives as selective cytotoxic agents
AU2024357861A1 (en) 2023-10-12 2026-04-23 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025193566A1 (en) * 2024-03-15 2025-09-18 Merck Sharp & Dohme Llc N-oxide derivatives as selective cytotoxic agents

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
CA2330304A1 (en) 1998-04-27 1999-11-04 Centre National De La Recherche Scientifique 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
IT1305313B1 (it) 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
ES2266258T3 (es) 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
PL227577B1 (pl) 2003-02-07 2017-12-29 Janssen Pharmaceutica Nv Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
CN1934093A (zh) 2004-01-12 2007-03-21 吉里德科学公司 嘧啶基膦酸酯抗病毒化合物和使用方法
CN1934092A (zh) 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
CN1946680B (zh) 2004-04-23 2011-04-06 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
EP1831157A2 (en) 2004-12-22 2007-09-12 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
CN101287702A (zh) 2005-10-19 2008-10-15 弗·哈夫曼-拉罗切有限公司 N-苯基苯乙酰胺非核苷逆转录酶抑制剂
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
EP2256115A1 (en) 2006-11-24 2010-12-01 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
KR20100088142A (ko) 2007-11-20 2010-08-06 머크 샤프 앤드 돔 코포레이션 비-뉴클레오사이드 역전사효소 억제제
CA2710987A1 (en) * 2008-01-08 2009-07-16 Merck Sharp & Dohme Corp. Process for preparing n-substituted hydroxypyrimidinone carboxamides
PL2924034T3 (pl) * 2010-03-30 2017-07-31 Merck Canada Inc. Kompozycja farmaceutyczna zawierająca nienukleozydowy inhibitor odwrotnej transkryptazy
WO2011126969A1 (en) 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Prodrugs of an hiv reverse transcriptase inhibitor
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP3785714A1 (en) 2014-04-01 2021-03-03 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors

Also Published As

Publication number Publication date
JP2015533123A (ja) 2015-11-19
JP5877281B2 (ja) 2016-03-02
CA2887312A1 (en) 2014-04-17
GT201500088A (es) 2017-09-28
DK2903977T3 (en) 2017-12-04
SI2903977T1 (sl) 2017-12-29
CN104822670B (zh) 2018-01-12
ME02918B (me) 2018-10-20
BR112015007742A2 (pt) 2017-08-08
EP3295942A1 (en) 2018-03-21
EP3656384A1 (en) 2020-05-27
MY192716A (en) 2022-09-05
NO2903977T3 (ar) 2018-02-17
RS59863B1 (sr) 2020-03-31
US20140100231A1 (en) 2014-04-10
PL3295942T3 (pl) 2020-05-18
HK1252786A1 (en) 2019-05-31
KR101696128B1 (ko) 2017-01-13
US20170349585A1 (en) 2017-12-07
EP3295942B1 (en) 2019-11-20
MD20150047A2 (ro) 2015-08-31
HK1207369A1 (en) 2016-01-29
AR092876A1 (es) 2015-05-06
SG11201502620UA (en) 2015-05-28
AU2013329552B8 (en) 2017-01-12
ES2909190T3 (es) 2022-05-05
BR112015007742B8 (pt) 2021-03-23
CN104822670A (zh) 2015-08-05
BR112015007742B1 (pt) 2021-01-19
EA033436B1 (ru) 2019-10-31
PH12015500764A1 (en) 2015-07-27
MX2015004448A (es) 2016-02-17
MX355040B (es) 2018-03-28
TW201623256A (zh) 2016-07-01
KR20150065186A (ko) 2015-06-12
TW201420576A (zh) 2014-06-01
NZ706729A (en) 2018-09-28
DK3656384T3 (da) 2022-04-19
NI201500048A (es) 2016-06-29
US10189831B2 (en) 2019-01-29
PT2903977T (pt) 2017-11-14
US9469634B2 (en) 2016-10-18
ZA201503143B (en) 2016-06-29
JP2016128470A (ja) 2016-07-14
WO2014058747A1 (en) 2014-04-17
TWI598343B (zh) 2017-09-11
LT3656384T (lt) 2022-05-10
UA114006C2 (xx) 2017-04-10
SI3295942T1 (sl) 2020-03-31
IL238090B (en) 2019-02-28
DK3295942T3 (da) 2020-02-10
TWI538907B (zh) 2016-06-21
CY1125202T1 (el) 2024-02-16
HRP20220502T1 (hr) 2022-05-27
CL2015000880A1 (es) 2015-08-28
PT3295942T (pt) 2020-02-18
RS56543B1 (sr) 2018-02-28
MD4625B1 (ro) 2019-04-30
HUE058903T2 (hu) 2022-09-28
LT2903977T (lt) 2017-12-11
US20160145255A1 (en) 2016-05-26
JP6097422B2 (ja) 2017-03-15
RS63112B1 (sr) 2022-05-31
CO7350655A2 (es) 2015-08-10
HRP20200158T1 (hr) 2020-08-07
EP3656384B1 (en) 2022-02-23
AU2013329552B2 (en) 2016-09-15
ECSP15018618A (es) 2019-06-30
HUE048670T2 (hu) 2020-08-28
AU2013329552C1 (en) 2016-12-22
PE20151787A1 (es) 2015-12-03
AP2015008355A0 (en) 2015-04-30
GEP20186838B (en) 2018-04-10
DOP2015000082A (es) 2015-08-16
PL2903977T3 (pl) 2018-01-31
TN2015000106A1 (en) 2016-06-29
ES2770774T3 (es) 2020-07-03
MD4625C1 (ro) 2019-11-30
US9718819B2 (en) 2017-08-01
EP2903977B1 (en) 2017-09-20
MA37959A2 (fr) 2017-12-29
CA2887312C (en) 2017-02-28
PH12015500764B1 (en) 2019-04-05
CY1119655T1 (el) 2018-04-04
EP2903977A1 (en) 2015-08-12
LT3295942T (lt) 2020-02-10
EA201590674A1 (ru) 2016-02-29
ES2645638T3 (es) 2017-12-07
SI3656384T1 (sl) 2022-05-31
AU2013329552A1 (en) 2015-04-16
CR20150183A (es) 2015-08-10
HRP20171819T1 (hr) 2017-12-29
HUE037231T2 (hu) 2018-08-28
PL3656384T3 (pl) 2022-04-04
CY1122585T1 (el) 2021-01-27
PT3656384T (pt) 2022-03-22

Similar Documents

Publication Publication Date Title
PH12015500764A1 (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
TN2012000455A1 (en) Non-nucleoside reverse transcriptase inhibitors
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
PH12018500292A1 (en) Antiviral beta-amino acid ester phosphodiame compounds
MX388757B (es) Profármacos de éster alifático antivíricos de tenofovir.
TN2009000243A1 (en) Non-nucleoside reverse transcriptase inhibitors
WO2008054605A3 (en) Non-nucleoside reverse transcriptase inhibitors
MX2016012915A (es) Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).
EA201170537A1 (ru) Ингибиторы вич-интегразы
WO2015017393A3 (en) Piperazine derivatives as hiv protease inhibitors
WO2011025683A8 (en) Hiv integrase inhibitors
WO2007002481A3 (en) Non-nucleoside reverse transcriptase inhibitors
TN2011000151A1 (en) Hiv integrase inhibitors
UA108495C2 (en) Reverse transcriptase nucleoside inhibitors
CY1116437T1 (el) Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης